<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01273181</url>
  </required_header>
  <id_info>
    <org_study_id>110062</org_study_id>
    <secondary_id>11-C-0062</secondary_id>
    <nct_id>NCT01273181</nct_id>
  </id_info>
  <brief_title>MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes</brief_title>
  <official_title>Phase I/II Study of Metastatic Cancer That Expresses MAGE-A3/12 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - MAGE-A3/12 is a type of protein commonly found on certain types of cancer cells,&#xD;
      particularly in metastatic cancer. Researchers have developed a process to take lymphocytes&#xD;
      (white blood cells) from cancer patients, modify them in the laboratory to target cancer&#xD;
      cells that contain MAGE-A3/12, and return them to the patient to help attack and kill the&#xD;
      cancer cells. These modified white blood cells are an experimental treatment, but researchers&#xD;
      are interested in determining their safety and effectiveness as a possible treatment for&#xD;
      cancers that involve MAGE-A3/12.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To evaluate the safety and effectiveness of anti-MAGE-A3/12 lymphocytes as a treatment for&#xD;
      metastatic cancers that have not responded to standard treatment.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Individuals at least 18 years of age who have been diagnosed with metastatic melanoma,&#xD;
      renal cell cancer, or another type of metastatic cancer that has not responded to standard&#xD;
      treatment.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened with a full medical history and physical examination, as&#xD;
           well as blood and urine tests, tumor samples, and imaging studies.&#xD;
&#xD;
        -  Participants will have leukapheresis to collect enough white blood cells for&#xD;
           modification in the laboratory.&#xD;
&#xD;
        -  Seven days before the start of anti-MAGE-A3/12 treatment, participants will have&#xD;
           chemotherapy with cyclophosphamide and fludarabine to suppress the immune system in&#xD;
           preparation for the treatment.&#xD;
&#xD;
        -  After the last dose of chemotherapy, participants will receive the anti-MAGE-A3/12 cells&#xD;
           as an infusion for 20 to 30 minutes, followed by a dose of interleukin-2 to keep the&#xD;
           anti-MAGE-A3/12 cells alive and active as long as possible. Participants will also&#xD;
           receive filgrastim to encourage the production of blood cells.&#xD;
&#xD;
        -  Participants will remain in the hospital to be monitored for possible side effects, and&#xD;
           after release from the hospital will have regular followup exams with blood samples and&#xD;
           imaging studies to evaluate the effectiveness of the treatment....&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background&#xD;
&#xD;
      We have constructed a single retroviral vector that contains both alpha and beta chains of a&#xD;
      T cell receptor (TCR) that recognizes the MAGE-A3/12 tumor antigen, which can be used to&#xD;
      mediate genetic transfer of this TCR with high efficiency (&gt; 30%) without the need to perform&#xD;
      any selection.&#xD;
&#xD;
      In co-cultures with human leukocyte antigen serotype within HLA-A serotype group (HLA-A2) and&#xD;
      MAGE-A3/12 double positive tumors, anti-MAGE-A3/12 TCR transduced T cells secreted&#xD;
      significant amounts of Interferon (IFN)-gamma with high specificity.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Primary objectives:&#xD;
&#xD;
        -  Determine if the administration of anti-MAGE-A3/12 engineered peripheral blood&#xD;
           lymphocytes and aldesleukin to patients following a nonmyeloablative but lymphoid&#xD;
           depleting preparative regimen will result in clinical tumor regression in patients with&#xD;
           metastatic cancer that expresses the MAGE-A3/12 antigen.&#xD;
&#xD;
        -  Determine the toxicity profile of this treatment regimen&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      -Determine the in vivo survival of TCR gene-engineered cells.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Patients who are human leukocyte antigen (HLA)-A*0201 positive and 18 years of age or older&#xD;
      must have:&#xD;
&#xD;
        -  metastatic cancer whose tumors express the MAGE-A3/12 antigen;&#xD;
&#xD;
        -  previously received and have been a non-responder to or recurred following standard care&#xD;
           for metastatic disease;&#xD;
&#xD;
      Patients may not have:&#xD;
&#xD;
      -contraindications for high dose aldesleukin administration.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      PBMC obtained by leukapheresis (approximately 10^10) cells) will be cultured in the presence&#xD;
      of anti-CD3 (OKT3) and aldesleukin in order to stimulate T-cell growth.&#xD;
&#xD;
      Transduction is initiated by exposure of approximately 10^7 to 5 X 10^8 cells to retroviral&#xD;
      vector supernatant containing the anti-MAGE-A3/12 TCR genes.&#xD;
&#xD;
      The study will begin by evaluating the safety of two ranges of cells, 5 x 10^9 - 3 x 10^10,&#xD;
      and greater than 3 x 10^10- 1 x 10^11 in a standard phase I dose escalation fashion using a&#xD;
      3+3 design. Once this safety has been confirmed, patients will be enrolled into the phase 2&#xD;
      portion of the trial using up to 1 x 10^11 cells. In the phase 2 portion, patients will be&#xD;
      entered into two cohorts based on histology: cohort 1 will include patients with metastatic&#xD;
      melanoma or renal cell cancer; cohort 2 will include patients with other types of metastatic&#xD;
      cancer.&#xD;
&#xD;
      Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen&#xD;
      consisting of cyclophosphamide and fludarabine followed by intravenous infusion of ex vivo&#xD;
      tumor reactive, TCR gene-transduced peripheral blood mononuclear cells (PBMC) plus&#xD;
      intravenous (IV) aldesleukin (720,000 IU/kg every (q)8h for a maximum of 15 doses).&#xD;
&#xD;
      Patients will undergo complete evaluation of tumor with physical examination, computed&#xD;
      tomography (CT) of the chest, abdomen and pelvis and clinical laboratory evaluation four to&#xD;
      six weeks after treatment. If the patient has stable disease (SD) or tumor shrinkage, repeat&#xD;
      complete evaluations will be performed every 1-3 months. After the first year, patients&#xD;
      continuing to respond will continue to be followed with this evaluation every 3-4 months&#xD;
      until off study criteria are met.&#xD;
&#xD;
      For each of the 2 strata evaluated in the phase 2 portion, the study will be conducted using&#xD;
      a phase II optimal design where initially 21 evaluable patients will be enrolled. For each of&#xD;
      these two arms of the trial, if 0 or 1 of the 21 patients experiences a clinical response,&#xD;
      then no further patients will be enrolled but if 2 or more of the first 21 evaluable patients&#xD;
      enrolled have a clinical response, then accrual will continue until a total of 41 evaluable&#xD;
      patients have been enrolled in that stratum.&#xD;
&#xD;
      For both strata, the objective will be to determine if the combination of high dose&#xD;
      aldesleukin, lymphocyte depleting chemotherapy, and anti-MAGE-A3/12 TCR-gene engineered&#xD;
      lymphocytes is able to be associated with a clinical response rate that can rule out 5%&#xD;
      (p0=0.05) in favor of a modest 20% partial response (PR) + complete response (CR) rate&#xD;
      (p1=0.20).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity Profile</measure>
    <time_frame>2 years</time_frame>
    <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Tumor Regression (Complete Response (CR) + Partial Response (PR)) in Patients With Metastatic Cancer</measure>
    <time_frame>2 years</time_frame>
    <description>Tumor regression response is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is a disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Metastatic Cancer</condition>
  <condition>Metastatic Renal Cancer</condition>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Ph I:Anti-MAGE A3/12 TCR PBL 5x10e9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.&#xD;
Note for phase I: The study will begin by evaluating the safety of two ranges of cells, 5x10^9-3x10^10, and greater than 3x10^10-1x10^11 in a standard phase I dose escalation fashion using a 3+3 design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph I:Anti-MAGE A3/12 TCR PBL 3x10e10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.&#xD;
Note for phase I: The study will begin by evaluating the safety of two ranges of cells, 5x10^9-3x10^10, and greater than 3x10^10-1x10^11 in a standard phase I dose escalation fashion using a 3+3 design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph II:Anti-MAGE TCR PBL MTD+HD IL-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase II:Anti-MAGE A3/12 TCR PBL MTD + HD IL-2, Melanoma, RCC&#xD;
Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.&#xD;
Note for phase II:patients will be entered into two cohorts based on histology:cohort 1 will include patients with metastatic melanoma or renal cell cancer; cohort 2 will include patients with other types of metastatic cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ph II:Anti-MAGE A3/12 TCR PBL MTD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase II: Anti-MAGE A3/12 TCR PBL MTD + HD-IL2 Other Cancer&#xD;
Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.&#xD;
Note for phase II:patients will be entered into two cohorts based on histology:cohort 1 will include patients with metastatic melanoma or renal cell cancer; cohort 2 will include patients with other types of metastatic cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes</intervention_name>
    <arm_group_label>Ph I:Anti-MAGE A3/12 TCR PBL 3x10e10</arm_group_label>
    <arm_group_label>Ph I:Anti-MAGE A3/12 TCR PBL 5x10e9</arm_group_label>
    <arm_group_label>Ph II:Anti-MAGE A3/12 TCR PBL MTD</arm_group_label>
    <arm_group_label>Ph II:Anti-MAGE TCR PBL MTD+HD IL-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aldesleukin</intervention_name>
    <description>720,000 IU/kg every 8 hours for a maximum of 15 doses</description>
    <arm_group_label>Ph I:Anti-MAGE A3/12 TCR PBL 3x10e10</arm_group_label>
    <arm_group_label>Ph I:Anti-MAGE A3/12 TCR PBL 5x10e9</arm_group_label>
    <arm_group_label>Ph II:Anti-MAGE A3/12 TCR PBL MTD</arm_group_label>
    <arm_group_label>Ph II:Anti-MAGE TCR PBL MTD+HD IL-2</arm_group_label>
    <other_name>IL-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>60 mg/kg/day x 2 days intravenous (IV)over 1 hour.</description>
    <arm_group_label>Ph I:Anti-MAGE A3/12 TCR PBL 3x10e10</arm_group_label>
    <arm_group_label>Ph I:Anti-MAGE A3/12 TCR PBL 5x10e9</arm_group_label>
    <arm_group_label>Ph II:Anti-MAGE A3/12 TCR PBL MTD</arm_group_label>
    <arm_group_label>Ph II:Anti-MAGE TCR PBL MTD+HD IL-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.</description>
    <arm_group_label>Ph I:Anti-MAGE A3/12 TCR PBL 3x10e10</arm_group_label>
    <arm_group_label>Ph I:Anti-MAGE A3/12 TCR PBL 5x10e9</arm_group_label>
    <arm_group_label>Ph II:Anti-MAGE A3/12 TCR PBL MTD</arm_group_label>
    <arm_group_label>Ph II:Anti-MAGE TCR PBL MTD+HD IL-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Metastatic cancer that expresses MAGE-A3/12 as assessed by one of the following methods:&#xD;
        reverse transcription polymerase chain reaction (RT-PCR) on tumor tissue defined as 30,000&#xD;
        copies of MAGE-A3/12 per 106 GAPDH copies, or by immunohistochemistry of resected tissue&#xD;
        defined as 10% or greater of cells being 2-3+, or serum antibody reactive with MAGE-A3/12.&#xD;
        Metastatic cancer diagnosis will be confirmed by the Laboratory of Pathology at the&#xD;
        National Cancer Institute (NCI).&#xD;
&#xD;
        Patients with melanoma or renal cell cancer must have previously received high dose&#xD;
        aldesleukin and have been either non-responders (progressive disease) or have recurred.&#xD;
        Patients with other histologies, must have previously received at least one systemic&#xD;
        standard care (or effective salvage chemotherapy regimens) for metastatic disease, if known&#xD;
        to be effective for that disease, and have been either non-responders (progressive disease)&#xD;
        or have recurred.&#xD;
&#xD;
        Greater than or equal to 18 years of age.&#xD;
&#xD;
        Willing to sign a durable power of attorney&#xD;
&#xD;
        Able to understand and sign the Informed Consent Document&#xD;
&#xD;
        Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1.&#xD;
&#xD;
        Life expectancy of greater than three months.&#xD;
&#xD;
        Patients of both genders must be willing to practice birth control for four months after&#xD;
        receiving the preparative regimen.&#xD;
&#xD;
        Patients must be human leukocyte antigen (HLA)-A*0201 positive&#xD;
&#xD;
        Serology:&#xD;
&#xD;
          -  Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental&#xD;
             treatment being evaluated in this protocol depends on an intact immune system.&#xD;
             Patients who are HIV seropositive can have decreased immune -competence and thus be&#xD;
             less responsive to the experimental treatment and more susceptible to its toxicities.)&#xD;
&#xD;
          -  Seronegative for hepatitis B antigen and hepatitis C antibody unless antigen negative.&#xD;
&#xD;
        Hematology:&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim.&#xD;
&#xD;
          -  White blood cell (WBC) (&gt; 3000/mm^3).&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3.&#xD;
&#xD;
          -  Hemoglobin greater than 8.0 g/dl.&#xD;
&#xD;
        Chemistry:&#xD;
&#xD;
          -  Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less or equal to&#xD;
             2.5 times the upper limit of normal.&#xD;
&#xD;
          -  Serum creatinine less than or equal to 1.6 mg/dl.&#xD;
&#xD;
          -  Total bilirubin less than or equal to 1.5 mg/dl, except in patients with Gilbert's&#xD;
             Syndrome who must have a total bilirubin less than 3.0 mg/dl.&#xD;
&#xD;
        More than four weeks must have elapsed since any prior systemic therapy at the time the&#xD;
        patient receives the preparative regimen, and patients' toxicities must have recovered to a&#xD;
        grade 1 or less (except for toxicities such as alopecia or vitiligo).&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Women of child-bearing potential who are pregnant or breastfeeding because of the&#xD;
        potentially dangerous effects of the preparative chemotherapy on the fetus or infant.&#xD;
&#xD;
        Active systemic infections, coagulation disorders or other major medical illnesses of the&#xD;
        cardiovascular, respiratory or immune system, myocardial infarction, cardiac arrhythmias,&#xD;
        obstructive or restrictive pulmonary disease.&#xD;
&#xD;
        Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).&#xD;
&#xD;
        Concurrent opportunistic infections (The experimental treatment being evaluated in this&#xD;
        protocol depends on an intact immune system. Patients who have decreased immune competence&#xD;
        may be less responsive to the experimental treatment and more susceptible to its&#xD;
        toxicities).&#xD;
&#xD;
        Concurrent Systemic steroid therapy&#xD;
&#xD;
        History of severe immediate hypersensitivity reaction to any of the agents used in this&#xD;
        study.&#xD;
&#xD;
        History of coronary revascularization or ischemic symptoms&#xD;
&#xD;
        Any patient known to have an left ventricular ejection fraction (LVEF) less than or equal&#xD;
        to 45%.&#xD;
&#xD;
        Documented LVEF of less than or equal to 45% tested in patients with:&#xD;
&#xD;
          -  History of ischemic heart disease, chest pain, or clinically significant atrial and/or&#xD;
             ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular&#xD;
             tachycardia, second or third degree heart block&#xD;
&#xD;
          -  Age greater than or equal to 60 years old&#xD;
&#xD;
        Documented forced expiratory volume 1 (FEV1) less than or equal to 60% predicted tested in&#xD;
        patients with:&#xD;
&#xD;
          -  A prolonged history of cigarette smoking (20 pk/year of smoking within the past 2&#xD;
             years).&#xD;
&#xD;
          -  Symptoms of respiratory dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A Rosenberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2011-C-0062.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001 May 17;411(6835):380-4. Review.</citation>
    <PMID>11357146</PMID>
  </reference>
  <reference>
    <citation>Berendt MJ, North RJ. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med. 1980 Jan 1;151(1):69-80.</citation>
    <PMID>6444236</PMID>
  </reference>
  <reference>
    <citation>Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006 May;6(5):383-93. Review.</citation>
    <PMID>16622476</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>January 7, 2011</study_first_submitted>
  <study_first_submitted_qc>January 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2011</study_first_posted>
  <results_first_submitted>February 14, 2013</results_first_submitted>
  <results_first_submitted_qc>February 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 27, 2013</results_first_posted>
  <last_update_submitted>October 6, 2015</last_update_submitted>
  <last_update_submitted_qc>October 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Steven Rosenberg, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Metastatic Cancer</keyword>
  <keyword>Clinical Response</keyword>
  <keyword>Metastatic Melanoma</keyword>
  <keyword>Metastatic Renal Cell Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Ph I:study will begin by evaluating the safety of 2 ranges of cells,5x10^9-3x10^10, &amp; &gt;3x10^10-1x10^11 in a standard ph I dose escalation using a 3+3 design. Ph II:pts will be entered into 2 cohorts based on histology:cohort 1 will include pts with metastatic melanoma or RCC; cohort 2 will include pts with other types of metastatic cancer.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I: Anti-MAGE A3/12 TCR PBL 5x10e9</title>
          <description>Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.</description>
        </group>
        <group group_id="P2">
          <title>Phase I:Anti-MAGE A3/12 TCR PBL 3x10e10</title>
          <description>Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.</description>
        </group>
        <group group_id="P3">
          <title>Phase II:Anti-MAGE A3/12 TCR PBL MTD+HD IL-2, Melanoma, RCC</title>
          <description>anti-MAGE A3/12 TCR PBL MTD + HD IL-2 Melanoma, RCC</description>
        </group>
        <group group_id="P4">
          <title>Phase II: Anti-MAGE A3/12 TCR PBL MTD +HD IL-2, Other Cancer</title>
          <description>anti-MAGE A3/12 TCR PBL MTD + HD IL-2 Other cancers</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase I, Dose 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study termination</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase I, Dose 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death during treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 2, Dose 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study termination</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 2, Dose 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death during treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase I: Anti-MAGE A3/12 TCR PBL 5x10e9</title>
          <description>Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.</description>
        </group>
        <group group_id="B2">
          <title>Phase I:Anti-MAGE A3/12 TCR PBL 3x10e10</title>
          <description>Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.</description>
        </group>
        <group group_id="B3">
          <title>Phase II:Anti-MAGE A3/12 TCR PBL MTD+HD IL-2, Melanoma, RCC</title>
          <description>Phase II:Anti-MAGE A3/12 TCR PBL MTD+HD IL-2, Melanoma, RCC&#xD;
Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.</description>
        </group>
        <group group_id="B4">
          <title>Phase II: Anti-MAGE A3/12 TCR PBL MTD +HD IL-2, Other Cancer</title>
          <description>Phase II: Anti-MAGE A3/12 TCR PBL MTD +HD IL-2, Other Cancer&#xD;
Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="1"/>
            <count group_id="B5" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.0" spread="11.4"/>
                    <measurement group_id="B2" value="39.7" spread="16.9"/>
                    <measurement group_id="B3" value="62.0" spread="0.0"/>
                    <measurement group_id="B4" value="71.0"/>
                    <measurement group_id="B5" value="51.9" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="00"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Toxicity Profile</title>
        <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I: Anti-MAGE A3/12 TCR PBL 5x10e9</title>
            <description>Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Phase I:Anti-MAGE A3/12 TCR PBL 3x10e10</title>
            <description>Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.</description>
          </group>
          <group group_id="O3">
            <title>Phase II:Anti-MAGE A3/12 TCR PBL MTD+HD IL-2, Melanoma, RCC</title>
            <description>Phase II:Anti-MAGE A3/12 TCR PBL MTD+HD IL-2, Melanoma, RCC&#xD;
Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>Phase II: Anti-MAGE A3/12 TCR PBL MTD +HD IL-2, Other Cancer</title>
            <description>Phase II: Anti-MAGE A3/12 TCR PBL MTD +HD IL-2, Other Cancer&#xD;
Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity Profile</title>
          <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Tumor Regression (Complete Response (CR) + Partial Response (PR)) in Patients With Metastatic Cancer</title>
        <description>Tumor regression response is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is a disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anti-MAGE TCR PBL 5x10e9 +HD IL-2</title>
            <description>anti-MAGE A3/12 TCR PBL 3x10e10 to 1 x 10e11 + HD IL-2&#xD;
Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Anti-MAGE TCR PBL 5x10e10 +HD IL-2</title>
            <description>anti-MAGE A3/12 TCR PBL 5x10e9 to 3 x 10e10 + HD IL-2&#xD;
Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.</description>
          </group>
          <group group_id="O3">
            <title>Anti-MAGE TCR PBL+HD IL-2, Mel, RCC</title>
            <description>anti-MAGE A3/12 TCR PBL MTD + HD IL-2 Melanoma, RCC&#xD;
Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>Anti-MAGE TCR PBL +HD IL-2, Other</title>
            <description>anti-MAGE A3/12 TCR PBL MTD +HD-IL-1 Other cancers&#xD;
Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Tumor Regression (Complete Response (CR) + Partial Response (PR)) in Patients With Metastatic Cancer</title>
          <description>Tumor regression response is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is a disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Phase I: Anti-MAGE A3/12 TCR PBL 5x10e9</title>
          <description>Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.</description>
        </group>
        <group group_id="E2">
          <title>Phase I:Anti-MAGE A3/12 TCR PBL 3x10e10</title>
          <description>Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.</description>
        </group>
        <group group_id="E3">
          <title>Phase II:Anti-MAGE A3/12 TCR PBL MTD+HD IL-2, Melanoma, RCC</title>
          <description>Phase II:Anti-MAGE A3/12 TCR PBL MTD+HD IL-2, Melanoma, RCC&#xD;
Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.</description>
        </group>
        <group group_id="E4">
          <title>Phase II: Anti-MAGE A3/12 TCR PBL MTD +HD IL-2, Other Cancer</title>
          <description>Phase II: Anti-MAGE A3/12 TCR PBL MTD +HD IL-2, Other Cancer&#xD;
Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)&#xD;
Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses&#xD;
PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :&#xD;
Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left ventricular diastolic dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT/SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>AST/SGOT (serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence/depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Speech impairment (e.g. dysphasia or aphasia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>PTT (partial thromboplastin time)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular &amp; nodal arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>fever of unknown origin without clinically or microbiologically documented infection) (ANC &lt;1.0 x 10e9/L, fever &gt;=38.5 degrees C)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Uric acid, serum-high (hyperuricemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-high (hypermagnesemia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Psychosis (hallucinations/delusions)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vascular leak syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Steven Rosenberg</name_or_title>
      <organization>National Cancer Institute, National Institutes of Health</organization>
      <phone>301-496-4164</phone>
      <email>sar@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

